Your browser doesn't support javascript.
Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle.
Stingl, Julia C.
  • Stingl JC; Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Germany.
BJPsych Open ; 8(1): e20, 2021 Dec 20.
Article in English | MEDLINE | ID: covidwho-1581952
ABSTRACT
In the article Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort, Catherine L. Clelland and colleagues for the first time suggest a protective effect of antidepressants against infection with coronavirus disease 2019 (COVID-19) itself. During the observation period of the first wave of the pandemic in New York, more than 50% of patients in the psychiatric hospital studied were infected. From retrospective analysis of the hospital medical records, the authors found a significantly lower risk for infection in patients with antidepressant medication compared to treatment with other psychiatric drugs. The findings of a reduced infection incidence in patients who were already on antidepressant drug therapy underlines a preventive efficacy of antidepressants against COVID-19. Taken together with the prior obtained data of efficacy against deterioration of COVID-19 disease, this study adds a piece of evidence to the positive benefit-risk of antidepressants in repurposing condition against COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: BJPsych Open Year: 2021 Document Type: Article Affiliation country: Bjo.2021.1075

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: BJPsych Open Year: 2021 Document Type: Article Affiliation country: Bjo.2021.1075